Citigroup Maintains Sell on Novavax, Raises Price Target to $8
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
Citigroup analyst Geoff Meacham maintains Novavax (NASDAQ:NVAX) with a Sell and raises the price target from $7 to $8.
Citigroup analyst Geoff Meacham maintains Novavax (NASDAQ:NVAX) with a Sell and raises the price target from $7 to $8.